Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Pfizer presents new mu-selective opioid receptor ligands and use thereof

Dec. 21, 2000

New use claimed by Sanofi-Synthelabo for succinic acid derivatives

Dec. 21, 2000

Commencement of phase I trial of IL-1 Trap for rheumatoid arthritis announced by Regeneron

Dec. 21, 2000

University of Utah to evaluate efficacy of glucosamine and chondroitin in treating OA

Dec. 20, 2000

Kaken patents new series with potential utility in inflammation, osteoporosis

Dec. 19, 2000

Anti-TNF-alpha MAb effective against spondyloarthropathy associated with Crohn's disease

Dec. 18, 2000

Recent patent covers selective COX-2 inhibitors synthesized at Merck Frosst

Dec. 15, 2000

Genmab moves HuMax-CD4 for RA to phase II

Dec. 15, 2000

Arakis and Penwest combine expertise to develop novel chronotherapeutic product for RA

Dec. 15, 2000

Profile of new COX-2 inhibitor discussed at Japanese medicinal chemistry meeting

Dec. 14, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.